Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis. Report of a case of mastocytosis associated with a lymphoplasmacytic lymphoma.

Abstract

In the present paper a case of a 65-year-old man diagnosed as suffering from a lymphoplasmacytic lymphoma, resistant to conventional chemotherapy, associated to a bone marrow (BM) mastocytosis, who was successfully treated with cladribine is reported. In this patient cladribine induced not only clinical remission of the lymphoplasmacytic lymphoma but it was also associated with immunophenotypical changes in the BM mast cells (MCs) compartment. Such changes were consistent with a decrease in the number of phenotypically aberrant (CD2+/CD25++/CD35++/CD69++/CD117++) MCs and the reappearance in the BM of MCs displaying a normal phenotype (CD2-/CD25-/CD35-/CD69+/CD117+++). Despite the potential utility of cladribine in the treatment of mastocytosis, our observations should be considered as preliminary and caution should be taken as regards the exact indications of the use of this purine analog in mastocytosis.

• Authors: Luis Escribano, Jaime Pérez de Oteyza, Rosa Núñez, Alberto Orfao
• Journal: Leukemia research (Leuk Res) Vol. 26 Issue 11 Pg. 1043-6 (Nov 2002) ISSN: 0145-2126 [Print] England
• PMID: 12363474 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antigens, CD
• Antineoplastic Agents
• Cladribine

Topics

• Aged
• Antigens, CD (immunology)
• Antineoplastic Agents (therapeutic use)
• Bone Marrow Cells (drug effects, immunology, pathology)
• Cladribine (therapeutic use)
• Humans
• Immunophenotyping
• Leukemia, Lymphocytic, Chronic, B-Cell (complications, drug therapy)
• Male
• Mast Cells (drug effects, immunology, pathology)
• Mastocytosis (drug therapy, etiology)